Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Miaoxin Fu
Institutions:
Hubei University of Medicine,
China National Pharmaceutical Group Corporation (China)
Observed institutions:
Hubei University of Medicine,
China National Pharmaceutical Group Corporation (China),
Dongfeng General Hospital
ORCID:
0009-0008-8726-0521
Observed ORCID:
0009-0008-8726-0521
OpenAlex ID:
A5000468209
Advancements in Cardiovascular Disease Research Affected by Smoking
2024
·
Miaoxin Fu
, Aihua Mei
, et al.
·
Reviews in Cardiovascular Medicine
·
27
PDF
The direct STAT3 inhibitor 6-ethoxydihydrosanguinarine exhibits anticancer activity in gastric cancer
2022
·
Xuewen Liu
, Xin Jin
, et al.
·
Acta Materia Medica
·
17
PDF
The clinical significance of T-cell regulation in hypertension treatment
2025
·
Miaoxin Fu
, Mingzhu Lv
, et al.
·
Frontiers in Immunology
·
13
Exendin-4 intervention attenuates atherosclerosis severity by modulating myeloid-derived suppressor cells and inflammatory cytokines in ApoE-/- mice
2024
·
Miaoxin Fu
, Qingmei Li
, et al.
·
International Immunopharmacology
·
5
Formation and remodeling of immunological niches in solid tumors: organ-specific architectures, inflammatory parallels, and therapeutic reprogramming
2026
·
Zhuo Zhang
, Yun Dong
, et al.
·
Frontiers in Immunology
PDF
Corrigendum to: The direct STAT3 inhibitor 6-ethoxydihydrosanguinarine exhibits anticancer activity in gastric cancer
2024
·
Xuewen Liu
, Xin Jin
, et al.
·
Acta Materia Medica
PDF
Show more works
View as search
Works count:
6
Citation count:
62
H-index:
4
I10-index:
3
Year
Topic
Type